

wings4innovation GmbH



Summary Info 2022

# New Translation Paradigm

*Translating scientific excellence into innovative therapies*



## *Partnering with academia to enable translation*



### Goals

- **Facilitate translation** of promising results from basic research into innovative therapies
- Support **commercialisation** of drug candidates
- Strengthen translational landscape in **Austria**: open to all Austrian academic research organisations

### KHAN-I

- w4i is the Austrian affiliate of KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I) to identify investment opportunities in Austria
- [www.khan-1.de](http://www.khan-1.de)



### w4i tasks

- Support transfer from basic to translational research by **developing drug discovery projects** together with the academic partners
- Scouting for, evaluation and joint generation of project proposals and investment opportunities
- Central contact for all Austrian research organisations
- Coordination of work packages of funded projects on behalf of KHAN-I
- Drug discovery consulting to academia

# Funding by KHAN-I

## *Partnering with academia to enable translation*



### *Requirements for funding*

- **Findings & hypotheses** that may lead to an innovative therapy (small molecules, biologics, ...) in **indications with high unmet medical need**
- In-depth scientific know-how at Principal Investigator (PI)
- Preexisting IP is not a prerequisite
- Technical feasibility, chance for commercialisation
- Approval by the w4i Advisory Board and the KHAN-I Investment Advisory Committee
- Close collaboration between w4i/KHAN-I and PI



### *Funding details*

- Supplementary and different to existing funding programmes/schemes
- Funding of important translational activities, i.e. defined work packages as part of a professional drug discovery program
- no funding of basic research or personnel possible
- Funding lead and decisions made by KHAN-I
- Specific experiments may be best performed by the project originator, either by in-kind contribution or by fully paid contract research
- all foreground IP is bundled by KHAN-I for commercialisation

**➔ *Call for project proposals is open until end of 2023***

# wings4innovation GmbH - Team



*Combining scientific and industrial expertise*



**Dr. Peter Nussbaumer**

Managing Director

- >35 years of industry experience in medicinal chemistry, drug discovery, and translational research
- PhD in organic chemistry from the TU Wien, Austria
- Managing Director at the Lead Discovery Center GmbH and Khanu Management GmbH in Dortmund, Germany and at wings4innovation GmbH



**Dr. Andreas Billich**

Translational Guide

- 30 years of industry experience, including group leader positions at Novartis in preclinical research on autoimmune and skin diseases
- PhD in biochemistry from the University of Münster, Germany
- Joined wings4innovation GmbH as Translational Guide in 2019



**Dr. Wolfgang Sommergruber**

Translational Guide

- 33 years of industry experience, including Scientific Director in Exploratory Research Oncology at Boehringer Ingelheim
- PhD in biochemistry from the University of Vienna
- Habilitation in Medical Biochemistry and Visiting Professor at University of Applied Sciences, Vienna
- Joined wings4innovation GmbH as Translational Guide in 2021




**Dr. Juliane Rademacher**

Translational Guide

- Experience in R&D strategy consulting and in evaluating investment opportunities in digital health and biopharma
- Dr.rer.nat in cell biology from the Free University in Berlin, funded by a stipend from a German-Israeli Research School in Cell Signaling and Gene Regulation
- Joined wings4innovation GmbH as Translational Guide in 2022

# Concept

*Process from first contact to successful commercialization*



colour code for parties involved in the various stages:

Project Originator	wings4innovation
Research Organisation	KHAN-I fund

# Framework Collaboration Partners



Agreement signed with 19 research institutions

